

## **BRIEF REPORT**

### **Increased risk of non-influenza respiratory virus infections associated with receipt of inactivated influenza vaccine**

Benjamin J. Cowling<sup>1</sup>, Vicky J. Fang<sup>1</sup>, Hiroshi Nishiura<sup>1,2</sup>, Kwok-Hung Chan<sup>3</sup>,  
Sophia Ng<sup>1</sup>, Dennis K. M. Ip<sup>1</sup>, Susan S. Chiu<sup>4</sup>, Gabriel M. Leung<sup>1</sup>, J. S. Malik Peiris<sup>1,5</sup>

#### **Affiliations:**

1. School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, China.
2. PRESTO, Japan Science and Technology Agency, Saitama, Japan.
3. Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, University Pathology Building, Queen Mary Hospital, Hong Kong Special Administrative Region, China.
4. Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Room 112, New Clinical Building, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, China.
5. Centre for Influenza Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, China.

**Corresponding author:**

Dr Benjamin J Cowling, School of Public Health, Li Ka Shing Faculty of Medicine,

The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong.

Tel: +852 3906 2011; Fax: +852 3520 1945; email: bcowling@hku.hk

**Alternate corresponding author if the corresponding author is unavailable:**

Professor Gabriel M. Leung, School of Public Health, Li Ka Shing Faculty of

Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong.

Tel: +852 3906 2001; Fax: +852 3520 1945; email: gmleung@hku.hk

Word count (abstract): 50

Word count (main text): 1,500

Running head: Flu vaccine and respiratory infections

Key words: influenza; vaccine; respiratory virus; interference

**Key points:**

Our experimental study provides evidence consistent with temporary non-specific immunity against other respiratory viruses following influenza virus infection, a phenomenon that could explain the epidemiologic dynamics of respiratory virus epidemics described in ecologic studies.

## **ABSTRACT**

We randomized 115 children to trivalent inactivated influenza vaccine (TIV) or placebo. Over the following 9 months, TIV recipients had increased risk of virologically-confirmed non-influenza infections (relative risk: 4.40; 95% confidence interval: 1.31-14.8). Being protected against influenza, TIV recipients may lack temporary non-specific immunity that protected against other respiratory viruses.

## **INTRODUCTION**

Influenza vaccination is effective in preventing influenza virus infections and associated morbidity in school-age children [1,2]. The potential for temporary non-specific immunity between respiratory viruses after an infection, and consequent ‘interference’ at the population level between epidemics of these viruses, has been hypothesized with limited empirical evidence to date mainly from ecological studies [3-15]. We investigated the incidence of acute upper respiratory tract infections (URTIs) associated with virologically-confirmed respiratory virus infections in a randomized controlled trial of influenza vaccination.

## **METHODS**

### ***Recruitment and follow-up of participants***

In a double-blind randomized controlled trial, we randomly allocated children aged 6-15 to receive 2008-09 seasonal trivalent influenza inactivated vaccine (TIV) (0.5ml Vaxigrip, Sanofi Pasteur) or placebo [16]. Serum specimens were drawn from subjects before vaccination in November–December 2008, one month after vaccination, in mid-study around April 2009, and at the end of the study in August–October 2009. Subjects were followed up for illnesses through symptom diaries and telephone calls, and illness reports in any household member triggered home visits where nasal and throat swabs (NTS) were collected from all household members. We defined the follow-up period for each subject from 14 days after receipt of TIV/placebo until collection of mid-study sera as the “winter” season and from collection of mid-study through final sera as the “summer” season.

Proxy written informed consent was obtained for all subjects from their parents or legal guardians, with additional written assent from those 8 years of age or older. The study protocol was approved by the Institutional Review Board of Hong Kong University.

### ***Laboratory methods***

NTS were tested for 19 respiratory viruses by the ResPlex II Plus multiplex array [17-19] and for influenza A and B by reverse-transcription polymerase-chain-reaction (RT-PCR) [16,20] (Appendix Text). We refer to infections determined by these assays as ‘confirmed’ infections. Information on influenza serology is provided in the Appendix Text.

### ***Statistical analysis***

We defined an acute respiratory illness (ARI) determined by self-reported signs and symptoms as at least any 2 of body temperature  $\geq 37.8^{\circ}\text{C}$ , headache, sore throat, cough, presence of phlegm, coryza, and myalgia [16]. We defined a febrile acute respiratory illness (FARI) as body temperature  $\geq 37.8^{\circ}\text{C}$  plus cough or sore throat. Because duration of follow-up varied by subject, we estimated the incidence rates of ARI and FARI episodes and confirmed viral infections overall and in the winter and summer seasons, and estimated the relative risk of these episodes for subjects who received TIV versus placebo via the incidence rate ratio using Poisson regression (Appendix Text). All statistical analyses were conducted in R version 2.11.0 (R Development Core Team, Vienna, Austria). Data

and syntax to reproduce these statistical analyses are available on the corresponding author's website.

## **RESULTS**

Among the 115 subjects who were followed up, the median (inter-quartile range) duration of follow-up was 272 (264, 285) days with no statistically significant differences in age, sex, household size or duration of follow-up between TIV and placebo recipients (Table 1). We identified 134 ARI episodes of which 49 met the more stringent FARI case definition. Illnesses occurred throughout the study period (Appendix Figure 1). There was no statistically significant difference in the risk of ARI or FARI between subjects who received TIV or placebo, either in winter or summer 2009 (Table 2).

We were able to collect 73 NTS for testing from 65/134 (49%) of subjects' ARI episodes, which included 22/49 (45%) of the FARI episodes. The average delay between ARI onset and collection of first NTS was 1.22 days and 5% of NTS were collected >3 days after illness onset, with no statistically significant differences between TIV and placebo recipients. We detected respiratory viruses in 32/65 NTS (49%) collected during ARI episodes, which included 12/22 (55%) of the FARI episodes. We collected 85 NTS from subjects at times when one of their household contacts reported an acute URTI but the subjects were not ill, and identified viruses in 3/85 (4%) including influenza A(H3N2), coxsackie/echovirus and coronavirus 229E.

There was no statistically significant difference in the risk of confirmed seasonal influenza infection between recipients of TIV or placebo although the point estimate was consistent with protection in TIV recipients (relative risk, RR: 0.66, 95% confidence interval, CI: 0.13, 3.27). TIV recipients had significantly lower risk of seasonal influenza infection based on serologic evidence (Appendix Text). However, subjects who received TIV had higher risk of ARI associated with confirmed non-influenza respiratory virus infections (RR: 4.40; 95% CI: 1.31, 14.8). Including 2 additional confirmed infections when subjects did not report ARI, subjects who received TIV had higher risk of confirmed non-influenza respiratory virus infections (RR: 3.46; 95% CI: 1.19, 10.1). The majority of the non-influenza respiratory virus detections were rhinoviruses and coxsackie/echoviruses and the increased risk among TIV recipients was also statistically significant for these viruses (Table 3). Most respiratory virus detections occurred in March 2009, shortly after a period of peak seasonal influenza activity in February 2009 (Figure 1).

## **DISCUSSION**

In our study in the pre-pandemic period, we did not observe a statistically significant reduction in confirmed seasonal influenza virus infections in the TIV recipients (Table 3), although serological evidence (Appendix Text) and point estimates of vaccine efficacy based on confirmed infections were consistent with protection of TIV recipients against the seasonal influenza viruses that circulated in January-March 2009 [16]. We identified a statistically significant increased risk of non-influenza respiratory virus infections among TIV recipients (Table 3), including significant increases in the risk of rhinovirus and coxsackie/echovirus

infections which were most frequently detected in March 2009 immediately following the peak in seasonal influenza activity in February 2009 (Figure 1).

The increased risk of non-influenza respiratory viruses among TIV recipients could be an artefactual finding, for example measurement bias could have resulted if subjects were more likely to report their first ARI episode but less likely to report subsequent episodes, while there was no real difference in rhinovirus or other non-influenza respiratory virus infections following the winter influenza season. The increased risk could also indicate a real effect. Receipt of TIV could increase influenza immunity at the expense of reduced immunity to non-influenza respiratory viruses, by some unknown biological mechanism. Alternatively, our results could be explained by temporary non-specific immunity following influenza virus infection, through the cell-mediated response or, more likely, the innate immune response to infection [21-23]. Subjects who received TIV would have been protected against influenza in February 2009 but then would not have had heightened non-specific immunity in the following weeks. They would then face a higher risk of certain other virus infections in March 2009 compared to placebo recipients (Figure 1). The duration of any temporary non-specific immunity remains uncertain [13] but could be of the order of 2-4 weeks based on these observations. It is less likely that the interference observed here could be explained by reduced community exposures during convalescence, i.e. behavioral rather than immunologic factors [14].



The phenomenon of virus interference has been well known in virology for over 60 years [24-27]. Ecological studies have reported phenomena potentially explained by viral interference [3-11]. Non-specific immunity against non-influenza respiratory viruses was reported in children for 1-2 weeks after receipt of live attenuated influenza vaccine [28]. Interference in respiratory and gastrointestinal infections has been reported following receipt of live oral poliovirus vaccine [29-32].

Our results are limited by the small sample size and the small number of confirmed infections. Despite this limitation we were able to observe a statistically significant increased risk of confirmed non-influenza respiratory virus infections among TIV recipients (Table 3). A negative association between serologic evidence of influenza infection and confirmed non-influenza virus infection in winter 2009 was not statistically significant (odds ratio: 0.27; 95% CI: 0.01, 2.05) (Appendix text). One must be cautious in interpreting serology in children who have received TIV [2,33]. Finally, acute URTI incidence was based on self-report with regular telephone reminders and we may have failed to identify some illnesses despite rigorous prospective follow-up.

Temporary non-specific immunity leading to interference between epidemics of respiratory viruses could have important implications. First, as observed in our trial, TIV appeared to have poor efficacy against acute URTIs (Table 2) apparently because the protection against influenza virus infections conferred by TIV was offset by an increased risk of other respiratory virus infections (Table 3). Second, interference between respiratory viruses could suggest new approaches

to mitigating epidemics [32]. Mass administration of live polio vaccine in children has been used to control enterovirus 71 epidemics [10,31]. Finally, viral interference could bias estimates of influenza vaccine effectiveness in test-negative case-control studies (Appendix text) [2,34-43]. One test-negative study reported an association between receipt of TIV and the risk of ILI associated with a non-influenza virus [38].

Further work is required to more fully characterize temporary non-specific immunity overall and within specific groups such as children. Animal studies [44-50] and volunteer adult human challenge studies [51] could provide useful evidence. Further community-based observational cohort studies, and community-based experimental studies such as our vaccine trial, may be particularly suitable for investigating temporary non-specific immunity since most acute URTIs do not require medical attention.

## **FUNDING**

This project was supported by the Area of Excellence Scheme of the Hong Kong University Grants Committee (grant no. AoE/M-12/06), the Hong Kong University Research Council Strategic Research Theme of Public Health, the Harvard Center for Communicable Disease Dynamics from the National Institute of General Medical Sciences (grant no. U54 GM088558), and the Research Fund for the Control of Infectious Disease, Food and Health Bureau, Government of the Hong Kong SAR (grant no. PHE-2). The funding bodies had no role in study design, data collection and analysis, preparation of the manuscript, or the decision to publish.

## **CONFLICTS OF INTEREST**

BJC has received research funding from MedImmune Inc., a manufacturer of influenza vaccines. DKMI has received research funding from F. Hoffman-La Roche Ltd. JSMP receives research funding from Crucell MV. The authors report no other potential conflicts of interest.

## **ACKNOWLEDGMENTS**

We thank Chan Kit Man, Calvin Cheng, Lai-Ming Ho, Ho Yuk Ling, Lam Yiu Pong, Tom Lui, Edward Ma, Loretta Mak, Gloria Ng, Joey Sin, Teresa So, Winnie Wai, Lan Wei, Jessica Wong, Eileen Yeung and Jenny Yuen for research support. We thank Sarah Cobey, Ed Goldstein, Heath Kelly, Nancy Leung, Marc Lipsitch, Ryosuke Omori, Mary Schooling and Joe Wu for helpful discussions.

## REFERENCES

1. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. *Cochrane Database Syst Rev* **2008**; (2):CD004879.
2. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. *Lancet Infect Dis* **2011**.
3. Glezen P, Denny FW. Epidemiology of acute lower respiratory disease in children. *N Engl J Med* **1973**; 288(10):498-505.
4. Glezen WP, Paredes A, Taber LH. Influenza in children. Relationship to other respiratory agents. *JAMA* **1980**; 243(13):1345-9.
5. Anestad G. Interference between outbreaks of respiratory syncytial virus and influenza virus infection. *Lancet* **1982**; 1(8270):502.
6. Nishimura N, Nishio H, Lee MJ, Uemura K. The clinical features of respiratory syncytial virus: lower respiratory tract infection after upper respiratory tract infection due to influenza virus. *Pediatr Int* **2005**; 47(4):412-6.
7. Linde A, Rotzen-Ostlund M, Zweyberg-Wirgart B, Rubinova S, Brytting M. Does viral interference affect spread of influenza? *Eurosurveillance* **2009**; 14(40).
8. Anestada G, Nordbo SA. Virus interference. Did rhinoviruses activity hamper the progress of the 2009 influenza A (H1N1) pandemic in Norway? *Med Hypotheses* **2011**; 77(6):1132-4.
9. Casalegno JS, Ottmann M, Duchamp MB, et al. Rhinoviruses delayed the circulation of the pandemic influenza A (H1N1) 2009 virus in France. *Clin Microbiol Infect* **2010**; 16(4):326-9.

10. Berencsi G, Kapusinszky B, Rigo Z, Szomor K. Interference among viruses circulating and administered in Hungary from 1931 to 2008. *Acta Microbiol Immunol Hung* **2010**; 57(2):73-86.
11. Mak GC, Wong AH, Ho WY, Lim W. The impact of pandemic influenza A (H1N1) 2009 on the circulation of respiratory viruses 2009-2011. *Influenza Other Respi Viruses* **2012**.
12. Wang Z, Malanoski AP, Lin B, et al. Broad spectrum respiratory pathogen analysis of throat swabs from military recruits reveals interference between rhinoviruses and adenoviruses. *Microb Ecol* **2010**; 59(4):623-34.
13. Kelly H, Barry S, Laurie K, Mercer G. Seasonal influenza vaccination and the risk of infection with pandemic influenza: a possible illustration of non-specific temporary immunity following infection. *Eurosurveillance* **2010**; 15(47).
14. Rohani P, Green CJ, Mantilla-Beniers NB, Grenfell BT. Ecological interference between fatal diseases. *Nature* **2003**; 422(6934):885-8.
15. Yang Y, Halloran ME, Daniels MJ, Longini IM, Burke DS, Cummings DA. Modeling competing infectious pathogens from a Bayesian perspective: application to influenza studies with incomplete laboratory results. *J Am Statist Assoc* **2010**; 105(492):1310-22.
16. Cowling BJ, Ng S, Ma ES, et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. *Clin Infect Dis* **2010**; 51(12):1370-9.
17. Han J, Swan DC, Smith SJ, et al. Simultaneous amplification and identification of 25 human papillomavirus types with Templex technology. *J Clin Microbiol* **2006**; 44(11):4157-62.

18. Brunstein J, Thomas E. Direct screening of clinical specimens for multiple respiratory pathogens using the Genaco Respiratory Panels 1 and 2. *Diagn Mol Pathol* **2006**; 15(3):169-73.
19. Li H, McCormac MA, Estes RW, et al. Simultaneous detection and high-throughput identification of a panel of RNA viruses causing respiratory tract infections. *J Clin Microbiol* **2007**; 45(7):2105-9.
20. Cowling BJ, Chan KH, Fang VJ, et al. Comparative epidemiology of pandemic and seasonal influenza A in households. *N Engl J Med* **2010**; 362:2175-84.
21. McGill J, Heusel JW, Legge KL. Innate immune control and regulation of influenza virus infections. *J Leukoc Biol* **2009**; 86(4):803-12.
22. Khaitov MR, Laza-Stanca V, Edwards MR, et al. Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. *Allergy* **2009**; 64(3):375-86.
23. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. *J Clin Invest* **1998**; 101(3):643-9.
24. Duffy CE. Interference between St. Louis encephalitis virus and equine encephalomyelitis virus (Western Type) in the chick embryo. *Science* **1944**; 99(2582):517-8.
25. Henle W, Henle G. Interference of inactive virus with the propagation of virus of influenza. *Science* **1943**; 98:87-9.

26. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proceedings of the Royal Society of London - Series B: Biological Sciences **1957**; 147(927):258-67.
27. Lindenmann J. From interference to interferon: a brief historical introduction. Philos Trans R Soc Lond B Biol Sci **1982**; 299(1094):3-6.
28. Piedra PA, Gaglani MJ, Riggs M, et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics **2005**; 116(3):e397-407.
29. Seppala E, Viskari H, Hoppu S, et al. Viral interference induced by live attenuated virus vaccine (OPV) can prevent otitis media. Vaccine **2011**; 29(47):8615-8.
30. Contreras G. Effect of the administration of oral poliovirus vaccine on infantile diarrhoea mortality. Vaccine **1989**; 7(3):211-2.
31. Shindarov LM, Chumakov MP, Voroshilova MK, et al. Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. Journal of Hygiene, Epidemiology, Microbiology, and Immunology **1979**; 23(3):284-95.
32. Voroshilova MK. Potential use of nonpathogenic enteroviruses for control of human disease. Prog Med Virol **1989**; 36:191-202.
33. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis **2011**; 203(9):1309-15.
34. Skowronski DM, Gilbert M, Tweed SA, et al. Effectiveness of vaccine against medical consultation due to laboratory-confirmed influenza: results from

- a sentinel physician pilot project in British Columbia, 2004-2005. *Can Commun Dis Rep* **2005**; 31(18):181-91.
35. Skowronski DM, Masaro C, Kwindt TL, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. *Vaccine* **2007**; 25(15):2842-51.
36. Belongia EA, Kieke BA, Donahue JG, et al. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results. *Vaccine* **2011**; 29(38):6558-63.
37. Cheng AC, Kotsimbos T, Kelly HA, et al. Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: a test-negative case control study. *Vaccine* **2011**; 29(43):7320-5.
38. Kelly H, Jacoby P, Dixon GA, et al. Vaccine effectiveness against laboratory-confirmed influenza in healthy young children: a case-control study. *Pediatr Infect Dis J* **2011**; 30(2):107-11.
39. Skowronski DM, De Serres G, Crowcroft NS, et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. *PLoS Med* **2010**; 7(4):e1000258.
40. Kissling E, Valenciano M, Cohen JM, et al. I-MOVE Multi-Centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe. *PLoS ONE* **2011**; 6(11):e27622.



41. Kelly HA, Grant KA, Fielding JE, et al. Pandemic influenza H1N1 2009 infection in Victoria, Australia: no evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009. *Vaccine* **2011**; 29(37):6419-26.
42. Orenstein EW, De Serres G, Haber MJ, et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. *Int J Epidemiol* **2007**; 36(3):623-31.
43. Fielding JE, Grant KA, Garcia K, Kelly HA. Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. *Emerg Infect Dis* **2011**; 17(7):1181-7.
44. Steel J, Staeheli P, Mubareka S, Garcia-Sastre A, Palese P, Lowen AC. Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment. *J Virol* **2010**; 84(1):21-6.
45. Imai K, Nakamura K, Mase M, Tsukamoto K, Imada T, Yamaguchi S. Partial protection against challenge with the highly pathogenic H5N1 influenza virus isolated in Japan in chickens infected with the H9N2 influenza virus. *Arch Virol* **2007**; 152(7):1395-400.
46. Van Reeth K, Gregory V, Hay A, Pensaert M. Protection against a European H1N2 swine influenza virus in pigs previously infected with H1N1 and/or H3N2 subtypes. *Vaccine* **2003**; 21(13-14):1375-81.
47. Kreijtz JH, Bodewes R, van den Brand JM, et al. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. *Vaccine* **2009**; 27(36):4983-9.
48. Domok I. Studies on the interaction between Coxsackie and poliomyelitis viruses. I. Simultaneous infection with B1 Coxsackie and Lansing poliomyelitis

viruses in mice of different ages. *Acta Microbiol Acad Sci Hung* **1957**; 4(2):183-95.

49. Domok I. Studies on the interaction between coxsackie and poliomyelitis viruses. III. The course of resistance to poliomyelitis virus induced by coxsackie B1 virus in young mice. *Acta Virol* **1959**; 3:222-33.

50. Duffy CE, Jordan RT, Meyer HM, Jr. Effect of multiple inoculations on interference between St. Louis encephalitis virus and equine encephalomyelitis virus. *Proc Soc Exp Biol Med* **1952**; 80(2):279-81.

51. Keitel WA, Couch RB, Quarles JM, Cate TR, Baxter B, Maassab HF. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. *J Infect Dis* **1993**; 167(2):305-11.

Table 1. Characteristics of subjects and duration of follow-up.

	TIV (n=69)	Placebo (n=46)
	n (%)	n (%)
Age group		
6-8 years	19 (28%)	16 (35%)
9-11 years	41 (59%)	27 (59%)
12-15 years	9 (13%)	3 (7%)
Female	30 (43%)	23 (50%)
Median duration of follow-up (days)	272	272
Mean number of individuals per household	3.7	3.6

Abbreviations: TIV = trivalent inactivated influenza vaccine.

Table 2. Incidence rates of acute upper respiratory tract infections among 115 subjects aged 6-15 years who received trivalent inactivated influenza vaccine (TIV) or placebo.

	TIV (n=69)		Placebo (n=46)		Relative risk (95% CI)		p-value
	Rate*	(95% CI)	Rate*	(95% CI)			
Winter 2009							
ARI <sup>†</sup> episodes	2080	(1530, 2830)	2260	(1550, 3300)	0.92	(0.57, 1.50)	0.74
FARI <sup>†</sup> episodes	609	(346, 1070)	753	(392, 1450)	0.81	(0.34, 1.92)	0.63
Summer 2009							
ARI <sup>†</sup> episodes	1510	(1130, 2020)	1160	(757, 1780)	1.30	(0.78, 2.18)	0.31
FARI <sup>†</sup> episodes	658	(424, 1020)	442	(221, 884)	1.49	(0.65, 3.38)	0.33

\* Incidence rates estimated as the number of ARI or FARI episodes per 1,000 person-years of follow-up.

† ARI defined as at least two of body temperature  $\geq 37.8^{\circ}\text{C}$ , cough, sore throat, headache, runny nose, phlegm and myalgia; FARI defined as body temperature  $\geq 37.8^{\circ}\text{C}$  plus cough or sore throat.

Abbreviations: TIV = trivalent inactivated influenza vaccine; CI = confidence interval; ARI = acute respiratory illness; FARI = febrile acute respiratory illness.

Table 3. Incidence rates of respiratory virus detections by RT-PCR and multiplex assay in respiratory specimens collected from 115 subjects aged 6-15 years who received trivalent influenza vaccine (TIV) or placebo, during 134 acute respiratory illness (ARI) episodes.

	TIV (n=69)			Placebo (n=46)			p-value
	n	Rate*	(95% CI)	n	Rate*	(95% CI)	
Any seasonal influenza	3	58	(19, 180)	3	88	(28, 270)	0.61
Seasonal influenza A(H1N1)	2	39	(10, 160)	2	59	(15, 240)	0.68
Seasonal influenza A(H3N2)	1	19	(3, 140)	0	0	(0, 88)	0.31
Seasonal influenza B	0	0	(0, 58)	1	29	(4, 210)	0.17
Pandemic influenza A(H1N1)	3	58	(19, 180)	0	0	(0, 88)	0.08
Any non-influenza virus <sup>†</sup>	20	390	(250, 600)	3	88	(28, 270)	<0.01
Rhinovirus	12	230	(130, 410)	2	59	(15, 240)	0.04
Coxsackie/echovirus	8	160	(78, 310)	0	0	(0, 88)	<0.01
Other respiratory virus <sup>‡</sup>	5	97	(40, 230)	1	29	(4, 210)	0.22

ARI episode with specimen collected but no virus detected	19	369	(235, 578)	14	412	(244, 696)	0.75
---	----	-----	------------	----	-----	------------	------

ARI episode with no specimen collected	41	796	(586, 1080)	28	824	(569, 1190)	0.89
--	----	-----	-------------	----	-----	-------------	------

---

\* Incidence rates estimated as the number of virus detections or illness episodes per 1,000 person-years of follow-up. Acute respiratory illness (ARI) defined as at least two of body temperature  $\geq 37.8^{\circ}\text{C}$ , cough, sore throat, headache, runny nose, phlegm and myalgia.

† In TIV recipients there were 4 detections with both rhinovirus and coxsackie/echovirus, and 1 detection with both coxsackie/echovirus and coronavirus NL63.

‡ including positive detections of coronavirus, human metapneumovirus, parainfluenza, RSV. The ResPlex II multiplex array tested for 19 virus targets including influenza types A and B (including 2009-H1N1), RSV types A and B, parainfluenza types 1-4, metapneumovirus, rhinovirus, coxsackievirus/echovirus, adenovirus types B and E, bocavirus, coronavirus types NL63, HKU1, 229E and OC43.

Abbreviations: TIV = trivalent inactivated influenza vaccine; ARI = acute respiratory illness; CI = confidence interval.

**FIGURE LEGENDS**





Figure 1. Timing of influenza and other respiratory virus detections in 115 subjects aged 6-15 years (panels A-D) compared to local influenza surveillance data (panel E). Solid red bars indicate detections in 69 subjects who received 2008-09 trivalent inactivated influenza vaccine, black dashed bars indicate detections in 46 subjects who received placebo. The bottom panel shows local laboratory surveillance data on the proportion of influenza virus detections among specimens submitted to the Public Health Laboratory Service. Fewer than 2% of PHLS specimens were positive for influenza B throughout the year.

*Footnote to Figure 1: 'Other viruses' included coronavirus, human metapneumovirus, parainfluenza, RSV.*





Appendix Figure 1. Incidence rates of acute upper respiratory tract infections in subjects who received trivalent inactivated influenza vaccine (TIV) or placebo. Panel (A) compares incidence rates of acute respiratory illness defined as at least two of body temperature  $\geq 37.8^{\circ}\text{C}$ , cough, sore throat, headache, runny nose, phlegm and myalgia; panel (B) compares incidence rates of febrile acute respiratory illness defined as body temperature  $\geq 37.8^{\circ}\text{C}$  plus cough or sore throat.